What are the Risk Factors, Treatment Options for Essential Thrombocythemia?

By Blood Cancer Talks - Last Updated: April 18, 2024

In this episode of “Blood Cancer Talks,” Raajit Rampal, MD, PhD, a Leukemia Specialist at the Memorial Sloan Kettering Cancer Center, joins hosts Raj Chakraborty, MD; Ashwin Kishtagari, MD; and Edward Cliff, MD; to discuss the diagnosis and management of essential thrombocythemia.

Specifically, they discuss the revised International Prognostic Score in Essential Thrombocythemia (IPSET), in which risk categories are defined by the presence of a prior thrombosis, age, and JAK2 mutation status.

Next, they give a rundown of essential thrombocythemia treatment options, such as anagrelide, ruxolitinib, and twice-daily aspirin. The podcast dives into the MAJIC-ET trial, a randomized, phase II study that observed no differences in hematological responses with ruxolitinib compared with best available therapy.

This podcast originally appeared on Blood Cancer Talks.

Dr. Samer Al Hadidi Discusses CAR-T MM Data Presented at the FDA ODAC Meeting

Ayalew Tefferi, MD, on Career Development as a Clinician-Investigator

Angela Dispenzieri, MD, on Managing Newly Diagnosed AL Amyloidosis

ASH 2023 Myeloid Recap With Anand Patel, MD

ASH 2023 Lymphoma Recap with Toby Eyre, MD

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer

What are the Risk Factors, Treatment Options for Essential Thrombocythemia?

Related